Reduced Opioid Marketing Could Limit Prescribing Information for Physicians-Reply
JAMA Intern Med
.
2018 Oct 1;178(10):1426-1427.
doi: 10.1001/jamainternmed.2018.4366.
Authors
Scott E Hadland
1
2
,
Magdalena Cerdá
3
,
Brandon D L Marshall
4
Affiliations
1
Grayken Center for Addiction, Boston Medical Center, Boston, Massachusetts.
2
Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts.
3
Department of Emergency Medicine, School of Medicine, University of California, Davis, Sacramento.
4
Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island.
PMID:
30285139
PMCID:
PMC7086487
DOI:
10.1001/jamainternmed.2018.4366
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Analgesics, Opioid*
Drug Industry
Humans
Marketing
Physicians*
Practice Patterns, Physicians'
Substances
Analgesics, Opioid
Grants and funding
K23 DA045085/DA/NIDA NIH HHS/United States
L40 DA042434/DA/NIDA NIH HHS/United States
R01 DA039962/DA/NIDA NIH HHS/United States